Format

Send to

Choose Destination
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14. doi: 10.1016/j.clon.2017.09.007. Epub 2017 Oct 13.

UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.

Author information

1
Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK. Electronic address: g.hanna@qub.ac.uk.
2
Department of Clinical Oncology, St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK.
3
National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, UK.
4
Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK.
5
Department of Radiotherapy, Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, UK.
6
Department of Radiotherapy, Beatson West of Scotland Cancer Centre, Glasgow, UK.
7
Department of Radiotherapy, Worcester Oncology Centre, Worcester, UK.
8
Department of Oncology, Guy's and St Thomas' Hospital, London, UK.
9
CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.

Abstract

Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between SABR studies and internationally.

KEYWORDS:

Constraints; OAR; SABR; SBRT; normal tissue; stereotactic radiotherapy

PMID:
29033164
DOI:
10.1016/j.clon.2017.09.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for White Rose Research Online
Loading ...
Support Center